Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroblastoma.

John M Maris1, Michael D Hogarty, Rochelle Bagatell

  • 1Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4318, USA. maris@chop.edu

Lancet (London, England)
|June 26, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Nature communications·2026
Same author

A generalizable system for antigenic peptide targeting across HLA-I allotypes.

bioRxiv : the preprint server for biology·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors.

Science advances·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial.

Lancet (London, England)·2026
See all related articles

Neuroblastoma, a complex pediatric cancer, shows significant heterogeneity. Understanding its biology and molecular pathogenesis is key to developing improved, risk-stratified therapies and novel treatments for better survival rates.

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Translational Research

Background:

  • Neuroblastoma exhibits significant clinical heterogeneity, impacting cure rates based on age, disease extent, and tumor biology.
  • Approximately 50% of neuroblastoma cases are high-risk, with poor survival (<40%) despite intensive treatment.
  • Tumor behavior ranges from spontaneous regression to relentless progression.

Purpose of the Study:

  • To review recent advances in neuroblastoma biology and molecular pathogenesis.
  • To outline the development of a uniform International Neuroblastoma Risk Group (INRG) classification system.
  • To summarize risk-based therapeutic strategies and discuss novel treatment approaches.

Main Methods:

  • Review of current literature on neuroblastoma biology and clinical management.

Related Experiment Videos

  • Discussion of proposed International Neuroblastoma Risk Group (INRG) classification.
  • Analysis of emerging molecular targets and therapeutic strategies.

    • Main Results:

    • Recent discoveries in molecular pathogenesis are translatable to clinical practice.
    • Development of a uniform INRG classification system is planned.
    • Novel therapeutic targets offer potential for more effective and less toxic treatments.

    Conclusions:

    • Understanding neuroblastoma's complex biology is crucial for improving outcomes.
    • Risk-based classification and targeted therapies are essential for high-risk patients.
    • Advances in molecular pathogenesis pave the way for improved treatment strategies with reduced toxicity.